These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 12483247)

  • 41. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
    Gervain J; Papp I; Csöndes M; Nemesánszky E; Rácz I; Ribiczey P; Telegdy L; Tornai I; Weisz G
    Orv Hetil; 2003 Jun; 144(25):1251-6. PubMed ID: 12901182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients.
    Wolters LM; van Nunen AB; Niesters HG; de Man RA
    Scand J Gastroenterol Suppl; 2000; (232):74-8. PubMed ID: 11232497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B.
    Ascione A; Ascione T; Lanza AG; Utech W; Di Costanzo GG; Macri M
    Hepatogastroenterology; 2006; 53(72):919-23. PubMed ID: 17153453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Viral breakthrough in HBeAg-negative chronic hepatitis B patients receiving lamivudine therapy].
    Chang YJ; Yim JY; Cho NY; Choi CW; Baek SJ; Ahn SH; Choi DW; Kwon YD; Kim SS; Kwon OS; Kim JH; Yeon JE; Song JW; Byun KS; Lee CH
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):397-404. PubMed ID: 12506244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical experience with lamivudine.
    Leung N
    Semin Liver Dis; 2002; 22 Suppl 1():15-21. PubMed ID: 12447725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term therapy of chronic hepatitis B with lamivudine.
    Lau DT; Khokhar MF; Doo E; Ghany MG; Herion D; Park Y; Kleiner DE; Schmid P; Condreay LD; Gauthier J; Kuhns MC; Liang TJ; Hoofnagle JH
    Hepatology; 2000 Oct; 32(4 Pt 1):828-34. PubMed ID: 11003630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B.
    Heijtink RA; Kruining J; Honkoop P; Kuhns MC; Hop WC; Osterhaus AD; Schalm SW
    J Med Virol; 1997 Nov; 53(3):282-7. PubMed ID: 9365897
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Optimal lamivudine treatment duration and the relationship between its early response and long term effect].
    He YW; Guo CX; Pan YF; Li SL; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):902-5. PubMed ID: 17196133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Chronic hepatitis B. Recent advances in diagnosis and treatment].
    Bernardi M; Biselli M; Gramenzi A
    Recenti Prog Med; 2002; 93(7-8):397-402. PubMed ID: 12138683
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B.
    Huang YW; Chayama K; Tsuge M; Takahashi S; Hatakeyama T; Abe H; Hu JT; Liu CJ; Lai MY; Chen DS; Yang SS; Kao JH
    Antivir Ther; 2010; 15(2):177-84. PubMed ID: 20386072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy.
    Kaplan DD; Reddy KR
    Am J Gastroenterol; 2002 Sep; 97(9):2465-7. PubMed ID: 12358276
    [No Abstract]   [Full Text] [Related]  

  • 54. A preliminary trial of lamivudine for chronic hepatitis B infection.
    Dienstag JL; Perrillo RP; Schiff ER; Bartholomew M; Vicary C; Rubin M
    N Engl J Med; 1995 Dec; 333(25):1657-61. PubMed ID: 7477217
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lamivudine resistance in hepatitis B: mechanisms and clinical implications.
    Fischer KP; Gutfreund KS; Tyrrell DL
    Drug Resist Updat; 2001 Apr; 4(2):118-28. PubMed ID: 11512520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response of pre-core mutant chronic hepatitis B infection to lamivudine.
    Rizzetto M; Volpes R; Smedile A
    J Med Virol; 2000 Jul; 61(3):398-402. PubMed ID: 10861653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [One year treatment with lamivudine in different hepatitis B virus related hepatic diseases].
    Buti M; Cotrina M; Cruz de Castro E; Jardí R; Rodríguez F; Esteban R; Guardia J
    Gastroenterol Hepatol; 1999 Mar; 22(3):117-21. PubMed ID: 10228320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.
    Perrillo RP; Wright T; Rakela J; Levy G; Schiff E; Gish R; Martin P; Dienstag J; Adams P; Dickson R; Anschuetz G; Bell S; Condreay L; Brown N;
    Hepatology; 2001 Feb; 33(2):424-32. PubMed ID: 11172345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant].
    Kim JK; Hwang SG; Park H; Choi HY; Cho HJ; Ko KH; Hong SP; Park PW; Kim NK; Rim KS
    Korean J Hepatol; 2005 Sep; 11(3):227-42. PubMed ID: 16177549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
    Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
    Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.